A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Solrikitug Formulation 1
Solrikitug Formulation 2
Research Site
Brisbane, Queensland, Australia
Incidence of Treatment-Emergent Adverse Events
Treatment-Emergent Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE) V4.0
Time frame: 165 days
Serum concentration of solrikitug
Pharmacokinetics (PK) of solrikitug in healthy participants
Time frame: 112 days
Concentration of Immunogenicity
Immunogenicity profile of solrikitug in healthy participants
Time frame: 112 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.